ClinicalTrials.gg
CompletedNCT03351322Updated Nov 24, 2020

ENERGI-F701 for Female Hair Loss Treatment

A Phase 2 interventional study of ENERGI-F701 and Regaine in Female Pattern Baldness, Hair Loss and Alopecia, sponsored by Energenesis Biomedical Co., Ltd.. Completed at 1 site in Taiwan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by Energenesis Biomedical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Alopecia with a site in Taiwan — 3 open to participants now, 5 under way, 2 of them phase 3. Alopecia · Taiwan.

Enrollment
7th of 18
67 · median 60
Started
2018
with 1 other
Phase 2
Only one
of the 19
Registered
6th of 19
by date
Lead sponsor
1 of 19
Energenesis Biomedical Co., Ltd.

Among the 19 studies in Alopecia with a site in Taiwan, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2018, is the only one in phase 2, and was the 6th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

3 of the 19 studies in Alopecia with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Alopecia with a site in Taiwan, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.

03

Conditions studied

  • Female Pattern Baldness
  • Hair Loss
  • Alopecia

Browse trials for

Keywords

  • Alopecia
  • Hair Loss
  • Female Pattern Baldness
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, aged at least 20 years old
  2. With hair loss over 100 hairs/day
  3. Willing to maintain the same hair style, color, shampoo and hair products used, and approximate hair length starting from signing ICF and throughout the study
  4. The subject of must show a negative urine or serum pregnancy test at Screening Visit
  5. Have signed the written form

Exclusion criteria

Exclusion Criteria:

Any subject meeting any of the exclusion criteria will be excluded from study participation.

  1. With alopecia areata or cicatricial alopecia
  2. With other scalp or hair disorders
  3. With prior hair transplant
  4. Use wigs or hair weaves
  5. Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study
  6. Have taken any topical or systemic prescription of OTC medications for treating hair loss, hair regrowth and/or hair volume
  7. Have used medications known to cause hair thinning, such as Coumadin and anti-depressants/anti-psychotics
  8. Have received chemotherapy/cytotoxic agents as well as radiation/laser/surgical therapy of the scalp
  9. Have initiated or terminated the use of hormones for or hormone replacement therapy within 6 months. Subject will also be excluded from the study if she plans to initiate or terminate the use of hormones for birth control or hormone replacement therapy during the study.
  10. With known or suspected any ingredients of study product and active control
  11. Any hematologic abnormalities.
  12. Any serum chemistry abnormalities.
  13. Pregnant, lactating, or premenopausal with but not adopting at least one form of birth control.
  14. Enrollment in any drug trial
  15. With any condition judged by the investigator that entering the trial may be detrimental to the subject
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    ENERGI-F701

    ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks

    Drug: ENERGI-F701

  • Active comparator
    Regaine

    Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks

    Drug: Regaine

Interventions

  • DrugENERGI-F701

    ENERGI-F701 are applied for treatment of hair loss.

  • Regaine are applied for treatment of hair loss.

06

What researchers measure

Primary outcomes

  1. The amount of hair loss

    Change of the amount of hair loss at Week 12 from baseline.(hair loss is defined as the collection of hairs after combing at the study site)

    Time frame: Week 12

Secondary outcomes

  1. The amount of hair loss at each post-treatment visit

    Time frame: Week 2, 4, 6, 8, 10

  2. The thickness and density of hair

    Change of hair thickness and density measured by phototrichogram at each post-treatment visit

    Time frame: Week 2, 4, 6, 8, 10, 12

  3. Investigator assessment at each post-treatment visit

    The hair loss will be assessed by the investigator using Investigator Photographic Assessment Questionnaire (IPAQ).The change from Baseline in hair growth will be assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased.

    Time frame: Week 2, 4, 6, 8, 10, 12

  4. The hair wash/shed hair count at each post-treatment visit

    Subjects will collect hairs full day, including after combing and hair-washing. Subjects should turn in these hair collections at each visit. The results will be averaged weekly.

    Time frame: Week 2, 4, 6, 8, 10, 12

  5. The subject satisfaction

    Subject satisfaction evaluated by Women's Androgenic Alopecia Quality of Life Questionnaire (WAA-QOL) at each post-treatment visit from baseline. WAA-QOL is a sixteen-question questionnaire to evaluate subjects' quality of life influenced by hair loss. Each question will be assessed using the following 7-point scale: 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = a good bit, 4 = quite a bit , 5 = very much, 6 = extremely.

    Time frame: Week 2, 4, 6, 8, 10, 12

07

Study locations

1 site
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Nov 2019, 18 months.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 22, 2017
StartActual
May 23, 2018
Primary completionActual
Nov 29, 2019
CompletionActual
Dec 26, 2019
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03351322
Collaborators
A2 Healthcare Taiwan Corporation
Responsible party
Sponsor
First posted
Nov 22, 2017
Start date
May 23, 2018
Primary completion
Nov 29, 2019
Completion
Dec 26, 2019
Last update
Nov 24, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion